Following CRL, Revance says it's clear on instructions for resubmitting BLA

Josh Sullivan

In October, the FDA handed Revance Therapeutics a CRL for its botox-based frown line therapy, and the company said that the deficiencies stemmed from a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Following CRL, Revance says it's clear on instructions for resubmitting BLA

Josh Sullivan

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

Fol­low­ing CRL, Re­vance says it's clear on in­struc­tions for re­sub­mit­ting BLA

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Following CRL, Revance says it's clear on instructions for resubmitting BLA